CNTA — Centessa Pharmaceuticals Share Price
Last trade - 00:00- $1.02bn
- $867.41m
- $6.85m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.78 | ||
| Price to Tang. Book | 4.78 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 150.11 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -52.7% | ||
| Return on Equity | -54.45% | ||
| Operating Margin | -2312.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 6.85 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 26th, 2020
- Public Since
- May 28th, 2021
- No. of Shareholders
- 7
- No. of Employees
- 77
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 113,044,244
- Address
- 3Rd Floor, 1 Ashley Road, ALTRINCHAM, WA14 2DT
- Web
- https://www.centessa.com/
- Phone
- Contact
- Kristen Sheppard
- Auditors
- KPMG LLP
Upcoming Events for CNTA
Similar to CNTA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:53 UTC, shares in Centessa Pharmaceuticals are trading at $9.10. This share price information is delayed by 15 minutes.
Shares in Centessa Pharmaceuticals last closed at $9.10 and the price had moved by +43.31% over the past 365 days. In terms of relative price strength the Centessa Pharmaceuticals share price has outperformed the S&P500 Index by +14.03% over the past year.
The overall consensus recommendation for Centessa Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Centessa Pharmaceuticals does not currently pay a dividend.
Centessa Pharmaceuticals does not currently pay a dividend.
Centessa Pharmaceuticals does not currently pay a dividend.
To buy shares in Centessa Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $9.10, shares in Centessa Pharmaceuticals had a market capitalisation of $1.03bn.
Here are the trading details for Centessa Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CNTA
Based on an overall assessment of its quality, value and momentum Centessa Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Centessa Pharmaceuticals is $14.20. That is 56.04% above the last closing price of $9.10.
Analysts covering Centessa Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.69 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Centessa Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -0.61%.
As of the last closing price of $9.10, shares in Centessa Pharmaceuticals were trading +8.99% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Centessa Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Centessa Pharmaceuticals' directors